Drug intelligence / Profile preview

FLU-Q-PAN H7N9 Formulation 1 + AS03B

Development stage: Unknown
Lead developer: GSK
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

FLU-Q-PAN H7N9 Formulation 1 + AS03B is a **combination vaccine** composed of an inactivated, split-virion monovalent Influenza A (H7N9) virus antigen (typically manufactured via propagation in embryonated hen’s eggs and subsequent inactivation and purification) together with the **AS03B adjuvant** (an oil-in-water emulsion containing squalene, DL-α-tocopherol, and polysorbate 80). This adjuvanted influenza vaccine is designed to improve immunogenicity against avian influenza A (H7N9) and is generally supplied as separate vials to be mixed immediately prior to use. The **mechanism of action** is induction of protective humoral immune responses (notably hemagglutination-inhibition antibodies) against the H7N9 virus, with AS03B enhancing the magnitude and breadth of this response. Clinical data support the use of adjuvanted H7N9 influenza vaccines to achieve greater immune responses than unadjuvanted comparators, particularly in pandemic preparedness scenarios due to the poor immunogenicity of unadjuvanted H7N9 vaccines[2]. Developers and manufacturers commonly include GSK (for the AS03B adjuvant) and Sanofi Pasteur (for the H7N9 antigen)[2].

Brand names: FLU-Q-PAN H7N9 Formulation 1 + AS03B
Other names: FLU-Q-PAN H7N9 Formulation 1 + AS03B

Targets

HA (Hemagglutinin)

Beyond the preview

Go deeper on FLU-Q-PAN H7N9 Formulation 1 + AS03B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FLU-Q-PAN H7N9 Formulation 1 + AS03B.

Explore the full profile